The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
Recruiting · NCT06988579 · Interventional (participants receive a specific treatment) · Lead sponsor: The First Affiliated Hospital of Guangzhou Medical University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation. This RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.
Who can take part
Inclusion criteria
- Aged 45-74 years
- Permanent resident of participating study communities
- No prior history of lung cancer and no lung cancer screening within the past 3 months
- Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up
Exclusion criteria
- Individuals with a confirmed diagnosis of lung cancer
- Those with severe comorbidities contraindicating CT imaging
- Inability to understand study protocols or provide informed consent due to cognitive impairment
- Concurrent participation in other clinical trials that may interfere with study outcomes
- Unable to comply with follow-up requirements
Where it is running
1 location listed.
- the First Affiliated Hospital of Guangzhou Medical University, - Guangzhou, Guangdong, China